ShareValue scores for LASA.NSE: Valuation 89, Quality 24, Growth 36, Health 42.

LASA.NSE
NSE

Lasa Supergenerics Limited

₹7.85(+2.48%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

13% to 30%
Valuation
89
Undervalued
Price vs Value
Quality
24
Weak
Business Strength
Growth
36
Weak
Revenue & Earnings
Health
42
Moderate
Financial Stability
Momentum
38
Bearish
Price Trend

Company Details

About

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026